Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14205104 | 0.92 | BCHE (0.50) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Hydrochloric Acid SCHEMBL4532989 | 0.91 | BCHE (0.49) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Trifluoroacetic Acid SCHEMBL4990251 | 0.88 | KDM1A (0.49) | KDM1AADRB2 | |
| SCHEMBL14172482 | 0.81 | BCHE (0.64) | BCHEADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL14172521 | 0.80 | BCHE (0.54) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Hydrochloric Acid SCHEMBL4502753 | 0.80 | BCHE (0.63) | BCHEADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL14205106 | 0.79 | DRD2 (0.42) | KDM1ABCHEADRB2ADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL4515033 | 0.78 | DRD2 (0.41) | KDM1ABCHEADRB2ADRB1ADRB3 | |
| SCHEMBL14172524 | 0.76 | PPARD (0.43) | KDM4EMAPTPPARD | |
| SCHEMBL14172490 | 0.75 | BCHE (0.65) | BCHEADRB2ADRB1ADRB3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507523-B2 | anticarcinogenic agents such as 6,7-dimethoxy-1-(4-pyridin-4-ylbenzyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride salt, used for treating gliomas or retinoblastomas; side effect reduction | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2013-08-13 | — | — | US | disclosed |
| US-20080146597-A1 | Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146597-A1 | Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy | TP53, MCL1, HRAS | KDM1A 2545/4885BCHE 3141/4885ADRB2 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.